IL18 and colitis: A pioneering study by Dashdorj et al. (59) showed that MitoQ, a mitochondria-targeted derivative of the antioxidant ubiquinone, endowed with antioxidant and anti-apoptotic properties, exerted beneficial effects on experimental colitis through a decrease in colonic NLRP3 and caspase-1 expression, with consequent decrease in IL-1β and IL-18 release (59).